Avifavir
The first Favipiravir-based drug in the world approved for the treatment of COVID-19
Research and development of medicines
Development and introduction in manufacture of innovative and reproduced synthetic and biotechnological Medicinal products "on a turn-key basis"
Investment activities
Investing in the development of innovative drugs; joint development of the projects of the ChemRar portfolio on partner terms; licensing and transfer of rights to the results of intellectual activity

«ChemRar» High-Tech center:

We develop and manufacture effective, safe and affordable medicines for the treatment of socially significant diseases and improvement of the quality of life:

• Using experience and global standards at all stages of creation of a novel medicine;

• Contributing to the development of the scientific and technological potential of the pharmaceutical industry in Russia;

• Applying our knowledge to search for optimal solutions for our partners.

COMPANY NEWS

RDIF and ChemRar have produced the first 100,000 courses of Avifavir In June Avifavir was delivered across Russia’s 35 regions More than 50 countries have expressed interest in importing Avifavir Moscow, July 2, 2020 - The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and ChemRar Group produced the first 100,000 ...

02.07.2020
Moscow, June 11, 2020 - The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar Group today announce the delivery of the first batch of Avifavir to Russian hospitals. Clinics and pharmaceutical organizations in the Moscow, Leningrad, Novgorod, Kirov and Nizhny Novgorod regions, as well as in the Republic of ...

11.06.2020
Moscow, June 8, 2020 - The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar Group note increasingly frequent cases of fraud related to the sale of drugs based on the Favipiravir active ingredient.   Scammers have created a number of fake websites and are posting private adverts on well-known websites, selling ...

08.06.2020
Avifavir is one of the two registered COVID-19 drugs in the world Avifavir is the first drug registered in Russia that has demonstrated efficacy against COVID-19 in clinical trials Avifavir has become the first Favipiravir-based drug in the world approved for treatment of COVID-19 Moscow, June 3, 2020 - The Russian Direct Investment Fund ...

03.06.2020
all news
Do you want to be aware of pharmaceutical news?
Subscribe to the weekly newsletter.
  
I agree to the processing of personal data. Privacy policy

EXPERT WORK AND INITIATIVES